Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Daily volatility informs risk tolerance and timing decisions. This overview highlights why investors should monitor volatility and adjust strategies.
28,131 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A wave of billionaire fund managers are boosting Amazon bets as AI hype collides with a value play. Pershing Square, ...
Anthropic’s safety-first AI stance is colliding with government pressure, placing its investors in a pivotal role as ...
Memory names rally on the AI memory supercycle thesis as demand for high-bandwidth memory and enterprise NAND keeps i...
Medicare largely offers no overseas coverage, leaving travelers with big medical bills. This report examines gaps, a ...
Rackspace sparked a momentum rally in the stock market today after announcing an AI cloud partnership with AMD. This ...
A circulating research note questions whether CoreWeave’s backlog is larger than investors expect, potentially signal...
Bitcoin surged toward a crucial resistance level as news spread that trump just flew china and a tech-heavy delegatio...
Morgan Stanley filed amended registrations for ETH and SOL ETF trusts with a 0.14% sponsor fee, aiming to set a new p...
A growing wave of market voices warns that the flood of easy investing access can erode returns. Carlson says many in...
Two clean-energy stock contenders—EOS and Plug Power—promise very different routes to a low-carbon future. This deep ...
A Hong Kong-based firm disclosed a $436 million stake in BlackRock’s IBIT, highlighting how offshore capital channels...